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Objectives: We performed gene expression profiling analysis using an experimental 
BPH rat model, which resembles human BPH pathology, to characterize the molecular 
features of BPH. 
Methods: Fetal urogenital sinus (UGS) isolated from 20-day-old male rat embryo was 
implanted into a pubertal male rat ventral prostate. The implanted UGS grew 
time-dependently, and the pathological findings at 3 weeks after implantation showed 
epithelial hyperplasia as well as stromal hyperplasia. Whole-genome oligonucleotide 
microarray analysis utilizing approximately 30,000 oligonucleotide probes was 
performed using prostate specimens during the prostate growth process (3 weeks after 
implantation). 
Results: Microarray analyses revealed 926 up-regulated (>2-fold change, p<0.01) and 
3,217 down-regulated genes (<0.5-fold change, p<0.01) in BPH specimens compared 
with normal prostate. Gene ontology analyses of up-regulated genes revealed 
predominant genetic themes of involvement in development (162 genes, p=2.01x10-4), 
response to stimulus (163 genes, p=7.37x10-13) and growth (32 genes, p=1.93x10-5). 
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When we used both normal prostate and non-transplanted UGSs as controls to identify 
BPH-specific genes, 507 and 406 genes were up-regulated and down-regulated, 
respectively. Functional network and pathway analyses showed that genes associated 
with apoptosis modulation by heat shock protein 70, IL-1, -2 and -5 signaling pathways, 
KIT signaling pathway, and secretin-like G-protein-coupled receptors, Class B, were 
relatively activated during the growth process in the BPH specimens. On the other hand, 
genes associated with cholesterol biosynthesis were relatively inactivated.  
Conclusion: Our microarray analyses of the BPH model rat may be useful of clarifying 
the molecular mechanism of BPH progression and identify molecular targets for BPH 
treatment. 
 








Benign prostatic hyperplasia (BPH) involves histologic changes of stromal and 
epithelial hyperplasia within discrete nodules that are generally located in the transition 
zone of the prostate [1,2]. Despite the spectacular new drug development and surgical 
successes achieved, the cellular and molecular processes underlying the pathogenesis 
and development of BPH remain poorly understood. Since we usually encounter 
patients with histologically developed BPH, it is difficult to investigate the prostate 
growth process in human BPH; therefore, there has been a need for a BPH animal 
model to provide us with molecular biological information and contribute to the 
identification of factors responsible for BPH. 
The main components of human BPH specimens are smooth muscle, a fibrous tissue 
element and collagen, which are the major components of the stromal extracellular 
matrix [3]. Histologically, prostate specimens of normal rodents are epithelial 
component-dominant. There are several BPH model rats, including testosterone-induced 
model rats and spontaneously hypertensive rats [4,5]. The histological characteristic of 
the testosterone-induced model rats is that they are epithelial component dominant 
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prostate specimens that are associated with ductal enlargement and epithelial dysplasia 
[6]. Spontaneously hypertensive rats (SHRs) exhibit features of glandular hyperplasia of 
the ventral prostate, including the narrowing of acini with epithelial protrusions into the 
lumen and the piling up of epithelial cells [4,7,8]. They are fairly different from human 
BPH, the pathological findings of which show both epithelial and stromal hyperplasia. 
Therefore, these models may not necessarily be suitable as BPH rat models to elucidate 
the molecular and cellular mechanisms involved, and the establishment of a rodent 
model that exactly reproduces the histopathological appearance of human BPH has been 
anticipated. Recently, a rat model of BPH produced by implanting fetal urogenital sinus 
(UGS) into adult rat ventral prostate was developed [6,9,10]. This rat model, which has 
the characteristics of having epithelial and stromal hyperplasia and resembling human 
BPH pathology, was produced based on the theory of embryonic reawakening in the 
pathogenesis of BPH [11]. Therefore, we considered that this BPH model rat may be 
useful to clarify the development and pathogenesis of BPH.   
In this study, in order to identify genes associated with the pathogenesis of BPH, we 
performed whole-genome oligonucleotide microarray analysis using the BPH model rat. 
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We also classified the expression of the differentially expressed genes by gene ontology 
analysis as well as functional network and pathway analysis in order to characterize the 




 We used a previously established experimental BPH model rat with pathologically 
stromal component-dominant hyperplasia (Fig. 1) [6,9,10]. Pregnant female rats that 
were at 20 days of pregnancy and 7-week-old male Sprague-Dawley (S-D) rats (Charles 
River Japan, Kanagawa, Japan) were used to produce a BPH model rat. First, we 
isolated 20-day-old male rat embryos from pregnant female rats. Second, the UGS was 
excised from the 20-day-old male rat embryos using a stereomicroscope. The trimmed 
UGS was washed with RPMI 1640 containing 10% fetal bovine serum and 1% 
penicillin/streptomycin. Third, the isolated UGS was implanted under the right ventral 
prostate capsule of 7-week-old adult male rats. After the host rats had been sacrificed 21 
days after UGS implantation, the right ventral prostate was dissected free of connective 
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tissue. The implanted UGS, initially weighing approximately 1 mg, grew 
time-dependently, being more than 100 mg at 21 days after implantation, as previously 
reported [6,9,10]. The study was performed in accordance with the Guidelines for the 
Care and Use of Experimental Animals and protocols approved by the Animal Care 
Committee of Fukushima Medical University (#26020). 
 
Total RNA isolation 
 Total RNA samples were isolated from implanted UGS harvested 21 days after 
implantation and the left ventral prostate (normal prostate) tissue of the same individual 
as a control with the RNeasy Midi Kit (Qiagen) in accordance with the manufacturer’s 
instructions. Samples in three groups of normal prostate (n=4), non-transplanted UGS 
(n=40) and transplanted UGS (BPH specimens; n=4) were used in this study.  
 
cRNA preparation and microarray analysis 
The cRNA preparation and microarray analysis were conducted at Bio Matrix 
Research (Chiba, Japan) using the Affymetrix system (Santa Clara, CA, USA). One 
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microgram of total RNA was converted into stranded cDNA using the One-Cycle cDNA 
Synthesis Kit. In vitro transcription reactions were performed using a GeneChip IVT 
Labeling Kit. After purification of biotin-labeled cRNA using GeneChip Sample 
Cleanup Module, the concentration of cRNA was measured, and then 15 µg of cRNA 
was fragmented in the presence of a fragmentation buffer. The 15 µg of cRNA was 
hybridized using the GeneChip Rat Genome 230 2.0 array on the GeneChip 
Hybridization Oven. After hybridization, the array was washed and stained with the 
GeneChip on the GeneChip Fluidics Station, and finally the array was scanned using the 
GeneChip Scanner 3000 7G to detect each signal. Candidate mRNAs showing 
differential expression were identified using the Affymetrix GeneChip Rat Genome 230 
2.0 array in accordance with the manufacturer’s instructions. Eleven probe pairs, each 
of which consisted of perfect match and mismatch probes with 25-mers of 
oligonucleotide, were prepared per transcript. The mismatch was designed as a 
single-base substitute for the perfect match probe, which had a sequence 




Microarray data analysis 
The expression value of the transcript was computed using GeneChip Operating 
Software. Normalization, relative signal intensities and fold changes among normal 
prostate, UGS and BPH specimens were calculated using Gene Spring○R 7.3.1 (Agilent 
Technologies, Santa Clara, CA, USA) data-mining software. Fold changes over 2.0 or 
under 0.5 and a p value <0.01 were considered to represent differential expression, and 
the significant genes in the BPH specimens were sorted by these criteria. The p values 
were calculated using Fisher’s exact test. 
  In the gene ontology analysis, the scored gene lists were analyzed with the GO 
browser in Gene Spring○R 7.3.1 (Bio Matrix Research, Chiba, Japan). In this analysis, in 
order to identify BPH-associated gene groups during growth, normal prostate was used 
as a control. 
The functional network and pathway analyses were performed using GeneMAPP 
Pathways software, one of the functions of Gene Spring○R 7.3.1 (Bio Matrix Research, 
Chiba, Japan). In this analysis, in order to identify BPH-specific gene groups during 
growth, both normal prostate and UGS were used as controls. Genes from the data set 
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were associated with cellular process, metabolic process, molecular function and 
physiological process in the GeneMAPP Pathways.  
 
Real-time Quantitative RT-PCR  
TaqMan PCR reagents for the 5 genes with the highest or lowest expression genes on 
the microarray were purchased from ABI (Applied Biosystems, CA), and applied 
according to the TaqMan Master Mix reagents kit protocol. The reactions were 
incubated for 2 min at 50°C, followed by denaturation for 10 min at 95°C. The reactions 
were run for 40 cycles of denaturation for 15 sec at 95°C, and an extension for 1 min at 
60°C per cycle using a StepOne real-time PCR System (Applied Biosystems, CA). The 
data were standardized against beta-actin gene expression using Pre-Developed TaqMan 
Assay Reagents (Applied Biosystems, CA).  
 
Results 
Whole-genome oligonucleotide microarray analysis utilizing approximately 30,000 
oligonucleotide probes was performed using normal prostate, non-transplanted UGSs 
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and transplanted UGSs (BPH specimens) during the process of growth of the prostate 
(21 days after implantation).  
First, we compared the expression level between BPH specimens and normal prostate 
in order to identify genes associated with the process of growth of the prostate in BPH 
model rat. Microarray analyses revealed 926 up-regulated genes (>2-fold change, 
p<0.01) and 3,217 down-regulated genes (<0.5-fold change, p<0.01) in BPH specimens 
compared with normal prostate. Quantitative RT-PCR reconfirmed the expression level 
of the highest (>30-fold change) or lowest expression genes (<0.1-fold change) on the 
microarray, and validated that these genes significantly increased or decreased, 
respectively. (Table 1, Fig. 2). 
We examined the expression of growth factor-, interleukin- and chemokine-related 
genes in BPH specimens because previous reports demonstrated that these genes were 
associated with the pathogenesis of BPH. As shown in Figure 3, some growth 
factor-related genes, interleukin-related genes and chemokine-related genes were 




In order to examine the genes significantly associated with BPH, we categorized the 
up-regulated and down-regulated genes by gene ontology analysis. This analysis was 
performed utilizing the three categories of biological process, cellular components and 
molecular function using the 926 up-regulated and 3,217 down-regulated genes in BPH 
specimens compared with normal prostate (Fig. 4). In terms of biological process, 
up-regulated genes were predominantly involved in 3 of 11 categories: development 
(162 genes, p=2.01x10-4), response to stimulus (163 genes, p=7.37x10-13) and growth 
(32 genes, p=1.93x10-5). Genes associated with organ development and morphogenesis 
in the category of development, and genes associated with cell growth and regulation of 
growth in the category of growth were prominent in BPH specimens. Genes associated 
with response to biotic stimulus, response to external stimulus and response to stress 
were also prominent. In these categories, genes associated with defense response, 
response to external biotic stimulus, response to wounding, response to pathogen or 
parasite, and immune response were included. In the categories of cellular components 
and molecular function, no sorted categories were found. Down-regulated genes were 
not involved in any of the 11 categories.  
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When we compared the expression levels of BPH specimens with those of both 
normal prostate and non-transplanted UGSs, 507 up-regulated genes (>2-fold change, 
p<0.01) and 426 down-regulated genes (<0.5-fold change, p<0.01) were identified in 
BPH specimens. These genes were considered to represent the BPH-specific gene 
expression profile because they were obtained by removing genes commonly highly or 
lowly expressed in both BPH and UGS specimens from the analysis. We performed 
functional network and pathway analyses using GeneMAPP Pathways software in terms 
of which kinds of pathways the genes up-regulated and down-regulated in BPH 
specimens, are involved in (Fig. 5). The 507 up-regulated and 426 down-regulated 
genes were categorized into pathways associated with cellular process, metabolic 
process, molecular function and physiological process. Figure 4 shows the percentages 
of significantly up-regulated (>2-fold change, p<0.01) and down-regulated (<0.5-fold 
change, p<0.01) genes among the total genes examined in each pathway category of 
cellular process, metabolic process, molecular function and physiological process. The 
higher the percentage of significantly up-regulated or down-regulated genes among the 
total genes, the more the pathway was considered to be activated or inactivated, 
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respectively. Pathways in which over 15% of the total genes were up-regulated in BPH 
specimens were apoptosis modulation by heat shock protein 70, IL-1, -2 and -5 
signaling pathway, and KIT signaling pathway in cellular process, and secretin-like 
G-protein-coupled receptors (GPCRs), Class B, in molecular process, suggesting that 
these pathways are relatively activated during the process of growth of the prostate in 
BPH specimens. On the other hand, pathways in which over 15% of the total genes 
were down-regulated in BPH specimens were cholesterol biosynthesis in metabolic 
process, suggesting that this pathway was relatively inactivated. Up-regulated and 
down-regulated genes in activated and inactivated pathways in BPH specimens are 
shown in Tables 2 and 3, respectively. In other pathways such as B-cell signaling 
pathway, p38 MAPK signaling pathway, eicosanoid synthesis, statin pathway, 
complement activation classical pathway, oxidative stress and protease degradation, a 
relatively large number of genes were up-regulated.  
 
Discussion 
Although several microarray studies have been conducted on human BPH tissues 
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[12,13], human BPH specimens were obtained from patients with advanced disease. 
Comparisons of genetic information between normal prostate and the BPH specimens 
during early growth have been limited in human study. In the present study, we 
performed microarray analysis using BPH model rats with both epithelial and stromal 
hyperplasia, resembling human BPH pathology, during prostate development, and 
compared the gene expression pattern between the normal prostate and BPH specimens 
in order to identify genes associated with the pathogenesis of BPH.  
Although the development of BPH requires the presence of testicular androgens, 
androgens do not necessarily cause BPH. Recently, therefore, researchers have focused 
on the androgen-independent pathway. Previous reports demonstrated that multiple 
families of growth factors, cytokines and chemokines act through paracrine signaling to 
stimulate proliferation [14-16]. In our microarray study using the BPH model, genes 
associated with growth factors, cytokines and chemokines were up-regulated in the 
BPH specimens compared with those in normal prostate, suggesting that this model 
could be suitable as a BPH rat model to elucidate the androgen-independent molecular 
and cellular mechanism involved in BPH. 
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Our microarray analyses revealed 926 up-regulated genes and 3,217 down-regulated 
genes in BPH specimens compared with those in normal prostate. We categorized the 
up- and down-regulated genes by gene ontology analysis. In the category of biological 
process, the up-regulated genes were subcategorized into 3 groups: development, 
response to stimulus and growth, in the BPH specimens. Since we examined the 
difference of gene expression between normal prostate and BPH specimens during the 
growth process, the up-regulation of genes associated with development and growth 
was to be expected. A noteworthy finding here is the up-regulation of genes associated 
with response to stimulus, including genes associated with response to biotic stimulus, 
external stimulus and stress. The presence of inflammatory cells infiltrating the prostate 
stroma and epithelium is an extremely common finding in human BPH specimens 
[17-19]. Inflammation may serve as the trigger for BPH by a chronic state of wound 
repair and tissue regeneration. Our genetic observations demonstrated that the genes 
associated with defense and immune response, and response to external biotic stimulus, 
wounding and pathogens could be activated in this BPH model, suggesting that external 
biotic stimulus and pathogens induce inflammation in the prostate and trigger prostatic 
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growth in aging human males.  
A wide range of signaling factors expressed in the UGS are expressed in the BPH as 
well, lending support to the concept that developmental growth pathways are 
reactivated in the adult prostate [20]. In our study, by removing genes commonly highly 
expressed or lowly expressed in both BPH and UGS specimens from the analysis, 507 
up-regulated genes and 426 down-regulated genes were identified, which were 
considered to represent the BPH-specific gene expression profile. These BPH-specific 
genes may be associated with BPH-specific growth. Using these genes, therefore, we 
performed functional network and pathway analyses to categorize the BPH-specific 
genes and detect the BPH-specific growth mechanism. We demonstrated a direct 
functional link between BPH pathogenesis and BPH-specific signaling pathways in the 
BPH model rat.  
As described above, the complex proinflammatory microenvironment is closely related 
to prostatic hyper-proliferation [17-20]. Prostatic inflammation observed in BPH may 
cause the release of some kinds of cytokines from inflammatory cells. These cytokines 
released from inflammatory cells may not only interact with immune effectors but also 
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with prostatic stromal and epithelial cells [20-24]. Inflammatory mediators may 
contribute to prostatic epithelial and stromal cell growth both directly, through the 
induction of growth via cytokines that stimulate the production of prostatic growth 
factors, and indirectly through decreases in prostate cell death via the down-regulation 
of prostate cell apoptosis [22,25]. Our functional network and pathway analyses showed 
that some interleukin signaling pathways were activated in BPH specimens. As 
described above, some interleukin-related genes were up-regulated in the BPH 
specimens compared with normal prostate specimens. Therefore, our findings suggest 
that these cytokines elicit changes in downstream signaling pathways and in the tissue 
microenvironment during BPH development in the BPH model.  
Our functional network and pathway analyses also suggested that the KIT receptor 
signaling pathway and cholesterol biosynthesis were associated with BPH pathogenesis. 
Previous reports have already shown the association of these pathways with the 
pathogenesis of BPH, and KIT regulated cell proliferation in the prostate plays a 
significant role in the pathophysiology of BPH [26]. The prostate synthesizes and stores 
a large amount of cholesterol, and prostate tissue is sensitive to changes in cholesterol 
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metabolism [27].  
We also found that novel pathways, including apoptosis modulation by heat shock 
protein 70 and secretin-like GPCRs, Class B, were likely to be associated with the 
development and growth of the prostate in the BPH model. In addition, some genes in 
other pathways, such as B-cell signaling pathway, p38 MAPK signaling pathway, 
eicosanoid synthesis, statin pathway, complement activation classical pathway, 
oxidative stress and protease degradation were up-regulated. There is a possibility that 
these pathways have a strong correlation with BPH pathogenesis. 
In our study, molecular profiling and classification of the BPH model identified some 
candidate genes and pathways associated with BPH pathogenesis. Further 
characterization of the genes and pathways obtained from the microarray analyses may 
identify the genes responsible for BPH and clarify their complex relationship, as well as 
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Figure 1. Histological findings of normal adult prostate (A,B,C), urogenital sinus 
before implantation (D,E,F) and BPH (G,H,I). In the BPH specimen, the proportion of 
the stromal components with smooth muscle and extracellular matrix was increased. In 
addition, the presence of inflammatory cells infiltrating the prostate stroma was found. 
Hematoxylin and eosin stain. A,D,G: x100. B,E,H: x200. C,F,I: x200. 
Figure 2. Quantitative RT-PCR on the highest (A; >30-fold change) or lowest (B; 
<0.1-fold change) expression genes extracted from microarray analysis. n=4 per group, 
*p<0.05, **p<0.01 
Figure 3. Average fold change of growth factor- (A), interleukin- (B) and 
chemokine-related genes (C) in BPH. *: p<0.01 
Figure 4. Gene ontology analyses using 926 up-regulated and 3,217 down-regulated 
genes in BPH samples compared with normal prostate. Number in parentheses each are 
the number of genes in each category. 
Figure 5. Percentage of significantly up-regulated (A, C, E, G) and down-regulated (B, 
D, F, H) genes among the total genes examined in each pathway of cellular process (A, 
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